arrow
K

Kathleen D. Liu

university of california–san francisco
H指数:86
被引数:3.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

External Validation, Molecular Signatures, and Therapeutic Relevance of Pediatric Sepsis-Associated Acute Kidney Injury Subphenotypes

儿科脓毒症相关性急性肾损伤亚型的外部验证、分子特征及其治疗相关性

2026-05-220
PRE
Longitudinal multiomic signatures of ARDS and sepsis inflammatory phenotypes identify pathways associated with mortality

ARDS和脓毒症炎症表型的纵向多组学特征识别与死亡率相关的途径

2026-02-020
OA
The Effects of Cyproheptadine on Severe COVID-19 From the I-SPY COVID Adaptive Platform Trial

Cyproheptadine对重症COVID-19的影响:来自I-SPY COVID适应性平台试验

2025-10-010
OAAI
Cytometry masked autoencoder: An accurate and interpretable automated immunophenotyper
2024-11-010
OAAI
Recommendations for clinical trial design in acute kidney injury from the 31st acute disease quality initiative consensus conference. A consensus statement
2024-08-080
OAAI
Acetaminophen for Prevention and Treatment of Organ Dysfunction in Critically Ill Patients With Sepsis
2024-08-063
OA
Rapidly improving ARDS differs clinically and biologically from persistent ARDS
2024-04-222
OAAI
Host and Microbe Blood Metagenomics Reveals Key Pathways Characterizing Critical Illness Phenotypes
2024-04-016
PRE
Molecular Phenotypes of Acute Respiratory Distress Syndrome in the ROSE Trial Have Differential Outcomes and Gene Expression Patterns That Differ at Baseline and Longitudinally over Time
2024-04-016
PRE
Sepsis-associated acute kidney injury: recent advances in enrichment strategies, sub-phenotyping and clinical trials
2024-03-217
OAAI
Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL)
2024-03-040
OAAI
Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL)

重组人碱性磷酸酶治疗脓毒症相关急性肾损伤 (REVIVAL) 的3期临床试验

2024-01-0317
OAAI